Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969212 | 1.00 | MME (0.49) | MMEACETAAR1MMEL1TP53 | |
| SCHEMBL11969159 | 0.93 | MME (0.52) | MMEACETAAR1MMEL1 | |
| SCHEMBL11969130 | 0.93 | MME (0.52) | MMEACETAAR1MMEL1 | |
| SCHEMBL11969079 | 0.92 | MME (0.58) | MMEACETP53 | |
| SCHEMBL9935983 | 0.85 | MME (0.61) | MMEACETAAR1 | |
| SCHEMBL9935980 | 0.85 | MME (0.61) | MMEACETAAR1 | |
| SCHEMBL11969171 | 0.84 | MME (0.61) | MMEACETP53 | |
| SCHEMBL11969637 | 0.83 | MME (0.52) | MMEACETAAR1MMEL1MAPK1 | |
| SCHEMBL11969626 | 0.83 | MME (0.52) | MMEACETAAR1MMEL1MAPK1 | |
| SCHEMBL11969147 | 0.83 | MME (0.49) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9487514-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2675792-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-14 | — | — | US | disclosed |
| US-8846913-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885TAAR1 446/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885TAAR1 446/4885 |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885TAAR1 446/4885 |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885TAAR1 446/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885TAAR1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.